Nootropics Index - Save on smarter supplements
Synthetic nootropics & research compounds

Memantine

3,5-dimethyladamantan-1-amine

Memantine is a prescription A glutamate-linked receptor involved in nerve-cell signaling.Source antagonist with clinical dementia evidence that does not establish cognitive enhancement in healthy adults. Compare listings by salt, release type, labeled strength and price per matched unit; prescription label doses and a long The time for blood levels to fall by half during the final elimination phase.Source do not define a nootropic regimen.

GlutamatergicSyntheticClinical ResearchLimited Human EvidenceMixed EvidencePopulation Specific EvidenceModerate Risk Profile
Updated October 2026/6 min read/14 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What memantine is

1

Memantine is a synthetic adamantane-derived prescription medicine that blocks NMDA receptors. Retail listings sometimes use nootropic language, while the main human evidence concerns a separate clinical population.

Clinical evidence has a different audience10
The dementia trial literature reports small, population-specific cognitive and functional effects. It does not establish benefit for healthy adults seeking memory, focus or productivity support.
02

Names, aliases and forms

Common NameMemantine
Chemical Name3,5-dimethyladamantan-1-amine
Salt FormMemantine hydrochloride
Brand NameNamenda
Trade NamesEbixa; Axura
03

Mechanisms of action

NMDA receptor antagonism

14

Memantine blocks the NMDA receptor channel in a moderate-affinity, uncompetitive manner. Receptor activity alone does not establish a consumer cognitive benefit.

04

Potential effects and evidence map

Clinical reviews find small, population-specific effects in moderate-to-severe Alzheimer-type dementia. Healthy cognitive enhancement is not established: small volunteer experiments have null cognitive outcomes or task-specific impairment, and clinical findings cannot supply a healthy-user benefit score.

Effect domainMagnitudeGrade
Memory / learning13
UnknownConfidence: Medium

Healthy memory enhancement is not established. Dementia trial findings do not quantify benefit for healthy adults.

Note The small healthy-volunteer trial at 30 mg found no verbal or visuospatial memory benefit and impaired one conditioning task; it is not a general safety or long-term efficacy estimate.

0/5
C
Focus / attention13
UnknownConfidence: Medium

Healthy attention enhancement is not established by the small volunteer evidence.

Note Null attention findings at 30 mg in 16 healthy men; this single experiment does not establish absence of every possible effect.

0/5
C
Cellular / long-term brain support14
UnknownConfidence: Medium

Receptor pharmacology does not establish general neuroprotection or long-term brain support in healthy adults.

Note Mechanistic rationale without a quantified healthy-user benefit.

0/5
D
05

Typical dosages and timing

Typical
5-20 mg/day
Not a recommendation
Lower bound
5 mg
Profile value
Upper bound
20 mg
Profile value
Label titration range15-20 mg/day

This is the U.S. immediate-release prescription label range, including clinical titration, rather than an established dose for healthy nootropic use. Product-specific prescribing instructions and release formulations are separate from retail serving claims.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Half-life1Acute
60-80 hours
Peak plasma concentration1

Label pharmacokinetics put the plasma concentration peak at 3-7 hours after oral dosing. This absorption timing does not establish the onset of a cognitive benefit.

Nootropic onset, duration and cycling1

A reliable healthy-user cognitive onset, single-dose effect duration and cycling schedule are not established. Plasma peak and half-life describe drug exposure. Clinical response and trial windows in dementia cannot define a healthy-user regimen.

07

Safety, side effects and risk profile

Accumulation over repeated dosing1
Slow elimination allows exposure to accumulate with repeated doses. A long half-life does not establish how long a desired cognitive effect lasts.
Why the base risk is moderate9
Meaningful impairment is the main concern: EU information flags driving effects, and a small healthy-volunteer study recorded dose-limiting dizziness and vomiting after 20 mg. This supports more than a low discomfort-only rating, while typical-use severe harm is not established strongly enough for a high rating. Prescription status, kidney disease, interactions and pregnancy are separate cautions; long-term healthy-use safety remains uncertain.
Legal / regulatory risk1
Confidence: High

As of 2026-10-19, U.S. labeling and EMA information identify memantine products as prescription medicines. National supply and import rules differ.

Note Regulatory status is a targeted access caution, not an intrinsic healthy-adult toxicity score.

Unscored
A
Interaction risk1
Confidence: High

Other NMDA antagonists and urine-alkalinizing drugs are explicit label cautions.

Note Examples include amantadine, ketamine, dextromethorphan, carbonic anhydrase inhibitors, and sodium bicarbonate.

3/5
A
Liver / kidney caution1
Confidence: High

Memantine is substantially renally cleared and label dosing changes in severe renal impairment.

Note Also note severe hepatic impairment caution from labeling.

3/5
A
Sedation / impairment4
Confidence: Medium

Dizziness and confusion can affect driving and other safety-sensitive tasks; EU information describes a minor-to-moderate driving influence.

Note Functional impairment matters beyond self-limited discomfort. Dementia-trial event rates cannot be applied numerically to healthy adults.

3/5
B
Headache / dizziness9
Confidence: High

Dizziness and vomiting caused one withdrawal after a single 20 mg dose in a small healthy-volunteer PK study; clinical labeling also lists dizziness and headache.

Note One event among 40 participants across several dose regimens; incidence and severity in routine healthy use remain uncertain.

2/5
A
GI discomfort2
Confidence: High

Constipation and vomiting are reported in clinical labeling; healthy-adult rates are not established.

Note Usually a tolerability concern; dose-limiting dizziness/vomiting in a healthy PK participant is discussed separately.

1/5
A
Pregnancy / lactation caution1
Confidence: Medium

U.S. labeling reports inadequate human pregnancy data and no human-milk data.

Note An evidence-gap caution for this population, not a quantified healthy-adult risk.

Unscored
B
Evidence uncertainty13
Confidence: High

Long-term safety and cognitive benefit in healthy nootropic users are insufficiently characterized.

Note Uncertainty does not itself establish a higher toxicity level.

Unscored
C
Special population1

The U.S. label contains a lower dose target for severe renal impairment and cautions for severe hepatic impairment. These are individual prescribing considerations; they do not establish a healthy-user dose.

Common effects2dizziness, headache, confusion, constipation

Dizziness, headache, confusion and constipation are the common adverse reactions in dementia-trial labeling. Their healthy-adult frequency cannot be inferred from those trials.

Clearance risk1

Renal clearance is sensitive to urine pH. The label warns that A higher urine pH state that can slow renal elimination of some medicines.Source can increase exposure; this can arise with certain medicines or clinical conditions.

Impairment caution4

EU product information describes a minor-to-moderate influence on driving and machine use. Dizziness or confusion can interfere with safety-sensitive activities.

08

Interactions and cautions

Combination caution1

Labeling says combined use with other NMDA antagonists has not been systematically evaluated and should be approached with caution.

Clearance interaction1

Labeling gives sodium bicarbonate and carbonic anhydrase inhibitors as examples that can shift urine pH and reduce memantine clearance. Alkaline urine can also occur in renal tubular acidosis or severe urinary-tract infections.

Practical caution1

Combination safety is not established for arbitrary nootropic stacks. Known label cautions for other NMDA antagonists are described above; speculative stack effects should not be assumed from individual-drug data.

10

Practical buying and quality notes

  • A price-comparison listing does not verify pharmacy authorization, prescription compliance, authenticity, strength or contaminant testing. Retail availability alone does not establish consumer suitability or local legality.1
  • Clinical products commonly contain memantine hydrochloride. EMA product information distinguishes the hydrochloride amount from its memantine-base equivalent. Match the release formulation, stated strength basis and units per pack before comparing price per unit; a tablet listed under capsules needs its original label checked.4
11

FAQ

Is memantine a supplement?

1

U.S. labeling and EMA information checked on 2026-10-19 describe prescription medicine products. Supplement-style retail marketing does not establish a lawful dietary-supplement classification.

Does memantine improve memory in healthy people?

13

No broad benefit is established. A small placebo-controlled study in 16 healthy men used a single 30 mg dose, found no significant verbal or visuospatial memory benefit, and impaired a conditioning task. Its dose and size limit generalization.

What does the prescription dosage range mean?

1

It describes immediate-release clinical labeling. It is not a validated healthy-user dose, and renal impairment or a different release formulation changes the prescribing context.

How long does memantine last, and is there a cycle?

1

The long half-life describes elimination rather than the duration of a cognitive benefit. Healthy-user effect duration and a validated nootropic cycling schedule are not established.

12

References

  1. DailyMed. Memantine hydrochloride tablets prescribing information.
  2. DailyMed. Memantine hydrochloride tablet patient information and adverse reactions.
  3. European Medicines Agency. Ebixa EPAR overview.
  4. European Medicines Agency. Ebixa EPAR product information.
  5. European Medicines Agency. Axura EPAR scientific discussion.
  6. U.S. Food and Drug Administration. Namenda (memantine hydrochloride) oral solution clinical pharmacology and biopharmaceutics review. NDA 21-627. 2005.
  7. NHS. Common questions about memantine.
  8. electronic Medicines Compendium. Memantine Mylan 10 mg film-coated tablets Summary of Product Characteristics.
  9. Liu MY, Meng SN, Wu HZ, Wang S, Wei MJ. Pharmacokinetics of single-dose and multiple-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clinical Therapeutics. 2008;30(4):641-653.
  10. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019.
  11. PubChem Compound Summary for CID 4054, Memantine.
  12. PubChem Compound Summary for CID 181458, Memantine hydrochloride.
  13. Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Loeschmann PA. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neuroscience Letters. 1997;224(1):57-60.
  14. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Current Opinion in Pharmacology. 2006;6(1):61-67.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.